Dr. Michael McCarthy has dedicated his career to the biotechnology field, working primarily in preclinical research on the potential use of biologics as treatments in the areas of infectious disease and oncology. Over the course of 21 years at MedImmune, Dr. McCarthy worked on several vaccine initiatives, including Lyme Disease, Parvovirus, and Uropathogenic E. coli, and served most recently as their Director of Infectious Disease/Vaccines Research and Head of the Vaccine Platform Group. His primary contributions while at MedImmune were to the Human Papillomavirus Virus-Like Particle program, where he developed the disassembly-reassembly process now used for commercial production of Gardasil and Cervarix. He also managed antiviral and antibacterial programs using either small molecule or antibody platforms, and supervised a group dedicated to assessing and implementing new enabling technologies related to infectious disease and vaccines. Dr. McCarthy continues to work in the biotechnology space as a consultant. 
Dr. McCarthy received his PhD in Biology from Wesleyan University in 1983, was a post-doctoral fellow at the University of California, San Francisco, in the Department of Biochemistry and Biophysics, and held a position as an Assistant Professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School.